Pheno Therapeutics granted two key patents protecting its selective GPR17 antagonist pipeline targeting neurological diseases
Pheno Therapeutics Limited. (Pheno), a clinical stage biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological and